NERV Share Price Performance
Recent NERV News & Updates
No updates
Minerva Neurosciences, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.89
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -205.8%
Minerva Neurosciences, Inc. Competitors
About NERV
- Founded
- 2007
- Employees
- 8
- CEO
- WebsiteView website
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 10.1%
- 1 Year: 17.7%
- Year to Date: 5.9%
Over the past 7 days, the market has dropped 2.7% with the Financials sector contributing the most to the decline. In the last year, the market is actually up 18%. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading